# Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer

> **NCT01081262** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 50 (actual)

## Conditions studied

- Borderline Ovarian Mucinous Tumor
- Ovarian Mucinous Cystadenocarcinoma
- Recurrent Fallopian Tube Carcinoma
- Recurrent Ovarian Carcinoma
- Stage IA Fallopian Tube Cancer AJCC v6 and v7
- Stage IA Ovarian Cancer AJCC v6 and v7
- Stage IB Fallopian Tube Cancer AJCC v6 and v7
- Stage IB Ovarian Cancer AJCC v6 and v7
- Stage IC Fallopian Tube Cancer AJCC v6 and v7
- Stage IC Ovarian Cancer AJCC v6 and v7
- Stage IIA Fallopian Tube Cancer AJCC v6 and v7
- Stage IIA Ovarian Cancer AJCC V6 and v7
- Stage IIB Fallopian Tube Cancer AJCC v6 and v7
- Stage IIB Ovarian Cancer AJCC v6 and v7
- Stage IIC Fallopian Tube Cancer AJCC v6 and v7
- Stage IIC Ovarian Cancer AJCC v6 and v7
- Stage IIIA Fallopian Tube Cancer AJCC v7
- Stage IIIA Ovarian Cancer AJCC v6 and v7
- Stage IIIB Fallopian Tube Cancer AJCC v7
- Stage IIIB Ovarian Cancer AJCC v6 and v7
- Stage IIIC Fallopian Tube Cancer AJCC v7
- Stage IIIC Ovarian Cancer AJCC v6 and v7
- Stage IV Fallopian Tube Cancer AJCC v6 and v7
- Stage IV Ovarian Cancer AJCC v6 and v7

## Interventions

- **BIOLOGICAL:** Bevacizumab
- **DRUG:** Capecitabine
- **DRUG:** Carboplatin
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Oxaliplatin
- **DRUG:** Paclitaxel
- **OTHER:** Quality-of-Life Assessment

## Key facts

- **NCT ID:** NCT01081262
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2010-10-12
- **Primary completion:** 2015-02-25
- **Final completion:** 2027-03-12
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2026-04-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01081262

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01081262, "Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT01081262. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*